You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

Details for Patent: 8,387,615


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 8,387,615 protect, and when does it expire?

Patent 8,387,615 protects SYMBICORT and is included in one NDA.

Protection for SYMBICORT has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has thirty-six patent family members in thirty countries.

Summary for Patent: 8,387,615
Title:Inhaler cap strap
Abstract: An inhaler (1) for dispensing doses of medicament from a container under user activation said inhaling which comprises a body (7) which includes a mouthpiece (5) through which the medicament is dispensed and a cap (2) which can be place in a position to substantially occlude the mouthpiece (5). The cap (2) is attached to said body (7) by a strap (3) which pivots from said body (7), said cap (2) being arranged to slide on the strap (3) such that the cap (2) must translate away from the mouthpiece (5) prior to the pivoting of the strap (3).
Inventor(s): Bunce; Martin (Marlborough, GB)
Assignee: AstraZeneca AB (Sodertalje, SE)
Application Number:10/579,481
Patent Claim Types:
see list of patent claims
Use; Delivery;
Patent landscape, scope, and claims:

Analyzing the Scope and Claims of United States Patent 8,387,615: A Comprehensive Guide

Introduction

Understanding the scope and claims of a patent is crucial for navigating the complex landscape of intellectual property. This article will delve into the details of United States Patent 8,387,615, exploring its claims, scope, and the broader patent landscape it inhabits.

Overview of the Patent

United States Patent 8,387,615, titled "Inhaler," is a patent that pertains to a device used for delivering medication, particularly in the context of respiratory conditions such as asthma and COPD. Here, we will break down the key components of this patent.

Claims Analysis

Independent Claims

The independent claims of a patent define the broadest scope of the invention. For Patent 8,387,615, these claims typically include descriptions of the inhaler device, its components, and how they function together to deliver medication.

  • Claim 1: This claim might describe the overall structure of the inhaler, including the housing, the medication container, and the actuation mechanism.
  • Claim 2: This could detail specific features such as the valve system, the dose counter, or other critical components.

Dependent Claims

Dependent claims build upon the independent claims, providing more specific details or variations of the invention.

  • Claim 3: This might specify a particular material used in the construction of the inhaler or a specific design feature that enhances usability.
  • Claim 4: This could describe a method of using the inhaler, including steps for loading the medication and actuating the device.

Scope of the Patent

The scope of a patent is defined by its claims and is critical for determining what is protected and what is not.

Device Patents vs. Medicine Patents

In the context of combination products like inhalers, there is often a distinction between device patents and medicine patents. Device patents, such as those for the inhaler in Patent 8,387,615, can extend patent protection beyond the expiration of the medicine patents, as seen in studies on patent evergreening[1].

Exclusivity and Market Impact

Device patents can significantly extend market exclusivity. For example, if the active ingredient patent has expired, but the device patent remains in force, competitors may be barred from producing a generic version of the inhaler, even if they can produce the generic medication itself. This can lead to continued market dominance for the original manufacturer[1].

Patent Landscape

Current Status and Expiration Dates

To understand the current status of Patent 8,387,615, one would need to check the latest information from the USPTO or other patent databases. This includes verifying the expiration date of the patent and any ongoing or past legal challenges.

Related Patents and Patent Families

Using tools like the USPTO's Patent Public Search or Global Dossier, one can identify related patents and patent families. This helps in understanding the broader intellectual property landscape and potential gaps or opportunities[4].

Patent Analytics and Claim Coverage

Claim Coverage Matrix

A Claim Coverage Matrix can be used to categorize patents by claims and scope concepts, helping to identify which patents and claims are actively protecting the intellectual property. This is particularly useful for managing large portfolios of patents and claims[3].

Interactive Claim Charts

Tools like ClaimScape® software generate interactive claim charts that can be reviewed by technical experts to determine the applicability of scope concepts to target products or methods. This helps in identifying gaps in current coverage and highlighting future design opportunities[3].

Legal and Regulatory Considerations

Claim Construction and Validity

Claim construction is a critical legal aspect that determines the scope of patent protection. Courts review claim construction de novo, and the claims must inform those skilled in the art with reasonable certainty[2].

Inter Partes Review (IPR)

Patents can be challenged through IPR proceedings, which can affect the validity of the claims. Understanding the outcomes of any IPRs related to Patent 8,387,615 is essential for assessing its current status and potential risks[2].

Industry Impact and Examples

Evergreening and Market Exclusivity

The practice of "evergreening," where manufacturers extend patent protection through device patents, can significantly impact the market. For instance, products like Atrovent HFA® and AUVI-Q® have seen extended patent protection due to device patents, delaying generic competition[1].

Competitive Landscape

In the respiratory medication delivery market, companies like Sanofi and Medtronic are key players. Understanding the patent landscape, including patents like 8,387,615, is crucial for these companies to maintain market position and innovate within the bounds of existing intellectual property[1].

Key Takeaways

  • Device Patents Extend Protection: Device patents can extend market exclusivity beyond the expiration of medicine patents.
  • Claims Analysis: Understanding independent and dependent claims is crucial for determining the scope of the patent.
  • Patent Analytics: Tools like Claim Coverage Matrix and interactive claim charts are essential for managing patent portfolios.
  • Legal Considerations: Claim construction and IPR proceedings can significantly impact the validity and scope of patent claims.
  • Industry Impact: Evergreening practices can delay generic competition and maintain market exclusivity.

FAQs

Q1: What is the significance of device patents in combination products? Device patents can extend market exclusivity beyond the expiration of the active ingredient patent, allowing manufacturers to maintain control over the market.

Q2: How do claim construction and IPR proceedings affect patent validity? Claim construction determines the scope of patent protection, and IPR proceedings can challenge the validity of patent claims, potentially affecting the patent's enforceability.

Q3: What tools are available for analyzing patent claims and coverage? Tools like Claim Coverage Matrix and interactive claim charts, such as those provided by ClaimScape® software, help in categorizing and analyzing patent claims and scope concepts.

Q4: How does the practice of "evergreening" impact the pharmaceutical industry? Evergreening extends patent protection through device patents, delaying generic competition and allowing original manufacturers to maintain market dominance.

Q5: Where can one find detailed information about a specific patent? Detailed information about a specific patent can be found through the USPTO's Patent Public Search, Global Dossier, or other patent databases.

Sources

  1. PLOS ONE: "Is Patent “Evergreening” Restricting Access to Medicine/Device Combinations? An Empirical Study of Combination Products in the United States"[1]
  2. CAFC: "VASCULAR SOLUTIONS LLC v. MEDTRONIC, INC."[2]
  3. Schwegman Lundberg & Woessner: "Patent Analytics"[3]
  4. USPTO: "Search for patents"[4]

More… ↓

⤷  Subscribe


Drugs Protected by US Patent 8,387,615

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Astrazeneca SYMBICORT budesonide; formoterol fumarate dihydrate AEROSOL, METERED;INHALATION 021929-001 Jul 21, 2006 AB RX Yes Yes 8,387,615*PED ⤷  Subscribe Y ⤷  Subscribe
Astrazeneca SYMBICORT budesonide; formoterol fumarate dihydrate AEROSOL, METERED;INHALATION 021929-002 Jul 21, 2006 AB RX Yes Yes 8,387,615*PED ⤷  Subscribe Y ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,387,615

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Sweden0303029Nov 17, 2003
PCT Information
PCT FiledNovember 10, 2004PCT Application Number:PCT/SE2004/001631
PCT Publication Date:May 26, 2005PCT Publication Number: WO2005/046774

International Family Members for US Patent 8,387,615

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 047124 ⤷  Subscribe
Austria E369167 ⤷  Subscribe
Australia 2004289156 ⤷  Subscribe
Brazil PI0416636 ⤷  Subscribe
Canada 2545445 ⤷  Subscribe
China 100493643 ⤷  Subscribe
China 1882371 ⤷  Subscribe
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.